WARFARIN SENSITIVITY BY GENOTYPING

This genetic test evaluates how an individual may respond to the anticoagulant drug warfarin by identifying specific genetic variations in genes like CYP2C9 and VKORC1. These genes influence how the body metabolizes and responds to warfarin, a drug commonly used to prevent blood clots. Understanding these variations helps in determining the most appropriate and safe dose for each individual, minimizing the risk of bleeding or clotting complications.

 Warfarin has a narrow therapeutic range, meaning that too much can lead to severe bleeding and too little can result in clot formation. Genetic variations can significantly alter a patient’s sensitivity to the drug. By identifying these variants in advance, clinicians can make more accurate dosing decisions from the beginning of treatment, leading to quicker stabilization and fewer adverse events.

This test is usually recommended before initiating warfarin therapy, particularly in patients at higher risk for bleeding or those who have had unpredictable responses to anticoagulants in the past. It may also be useful in patients requiring long-term anticoagulation to establish a stable regimen early on.

The results classify patients into categories such as normal, sensitive, or highly sensitive responders. Those with certain CYP2C9 or VKORC1 variants may require lower starting doses. Based on the findings, clinicians can individualize warfarin therapy to improve patient safety and efficacy.

A blood or buccal swab sample is collected and analyzed using PCR-based genotyping methods to detect known variants in the CYP2C9 and VKORC1 genes. Results are typically available within a few days and can be used immediately to guide dosing decisions.